PET in preclinical AD: image harmonization, characterization of the centiloid metric of Aβ load and associations with tau fluid biomarkers
This thesis explores technical factors influencing brain PET quantification, developing brain PET harmonization framework, assessing Centiloid robustness as a clinical biomarker, and evaluating the associations between fluid biomarkers and amyloid and tau PET imaging in the early stage of preclinica...
| Author: | |
|---|---|
| Format: | Doctoral thesis |
| Status: | Published version |
| Publication date: | 2024 |
| Country: | España |
| Institution: | CBUC, CESCA |
| Repository: | TDR. Tesis Doctorales en Red |
| OAI Identifier: | oai:www.tdx.cat:10803/690636 |
| Online Access: | http://hdl.handle.net/10803/690636 |
| Access Level: | Open access |
| Keyword: | Preclinical Alzheimer’s Disease Fluid biomarkers PET Harmonization Enfermedad de Alzheimer Preclínica Biomarcadores en Fluidos Harmonización Malaltia d'Alzheimer Preclínica Biomarcadors en Fluids Harmonització 616.8 |
| Summary: | This thesis explores technical factors influencing brain PET quantification, developing brain PET harmonization framework, assessing Centiloid robustness as a clinical biomarker, and evaluating the associations between fluid biomarkers and amyloid and tau PET imaging in the early stage of preclinical AD. Findings support prospective and retrospective harmonization using the developed framework, soon to be EARL accreditation's new harmonization criteria for brain PET imaging. Centiloid metric showed to be a robust metric, that can be used as a reliable biomarker. Additionally, promising results from CSF and blood biomarker studies, notably new blood biomarkers (blood ptau231 and ptau217), revealed their predictive abilities of for amyloid progression and moderate correlations with tau PET signals. This underscores their potential as valuable tools for cohort enrichment and recruitment of clinical trials. The thesis's outcomes contribute to the EARL accreditation program's first brain PET harmonization guideline, EMA approval for Centiloid use in clinical routine studies, and improving the understanding of new blood biomarkers and their application in preclinical AD. |
|---|